Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: POLETO who wrote (382)	1/27/1999 7:39:00 PM
From: Lawrence Burg	Read Replies (1) \| Respond to of 428

I know...I know...:o) In a big way. I'll check the TA, but it seems kinda obvious that the behavior has been caught back up by the underlying trends...

To: POLETO who wrote (382)	2/25/1999 6:56:00 PM
From: blackmerlin	Read Replies (1) \| Respond to of 428

CYPH may advance in price due to a wonderful announcement made today dealing with various approaches to its taxol development program: Thursday February 25, 12:56 pm Eastern Time Company Press Release SOURCE: Cytoclonal Pharmaceuticals, Inc. Cytoclonal Receives Taxol Payment; Company Also Announces Discovery of New Gene for Drug Production DALLAS, Feb. 25 /PRNewswire/ -- Cytoclonal Pharmaceutics Inc. (Nasdaq: CYPH - news, CYPHW - news, CYPHZ - news) announced today that it has received its first payment of the year from Bristol-Myers Squibb as part of its agreement with the drug giant for the production of paclitaxel (Taxol®). Cytoclonal signed a license and research agreement last year with BMS for rights to its fermentation production system and genes for BMS' blockbuster drug, Taxol. The Company also announced it has identified a new gene involved in production of the chemotherapeutic agent. The identification of the new gene in the Taxol pathway by Dr. Rodney Croteau of Washington State University, under work sponsored by Cytoclonal, represents another important step in further optimizing production of paclitaxel. Dr. Croteau previously isolated the gene for Taxadiene Synthase, another central enzyme in the pathway of paclitaxel production. ''Fermentation and genetic engineering are two key technologies for successful production of many drugs that are effective and efficient,'' said Arthur P. Bollon, Ph.D., Chief Executive Officer of Cytoclonal. Production of Taxol currently relies on needles from the rare Yew tree. But Cytoclonal has been developing a method of making the anti-cancer agent through genetic engineering and fermentation that could be more cost effective -- leading to its important deal with BMS. Sales of Taxol in 1998 exceeded $1.2 billion. Cytoclonal Pharmaceutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic and diagnostic products for the treatment and prevention of cancer and infectious diseases. The Company recently introduced a new rational drug design methodology, called Quantum Core Technology(TM), to create drugs for various diseases including lead compounds for cancer and viral infections. The Company's lead programs involve paclitaxel production using fermentation, the treatment of Polycystic Kidney Disease using paclitaxel and breast cancer treatment by peptide inhibition of estrogen receptors. Other programs include the discovery of human genes through Retroselection(TM), diagnosis and treatment of lung cancer, anti-sense therapeutics and mycobacteria-based vaccines. Except for historical information, the matters discussed in this news release may be considered ''forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. SOURCE: Cytoclonal Pharmaceuticals, Inc." The above article is included for information purposes only about Cytoclonal Pharmaceuticals, Inc. As always, one should consider the total of the public information readily available on a particular stock before making any investment decision. Regards, Jake Blackmerlin